SLC5A2 and chronic kidney disease: The findings of a randomized controlled trial suggest 7.4 more years of survival free of kidney failure with the combination of renin angiotensin system inhibitors and SGLT2 inhibitors in patients with albuminuric CKD without diabetes (56).